Coronavirus Disease-2019 Pandemic: Hopes Ride High on Targeting Known Drugs against Unkown.
作者信息
Mahalmani Vidya M, Mahendru Dhruv, Sarma Phulen, Prakash Ajay, Medhi Bikash
机构信息
Department of Pharmacology, PGIMER, Chandigarh, India.
出版信息
Indian J Pharmacol. 2020 Mar-Apr;52(2):75-78. doi: 10.4103/ijp.IJP_309_20. Epub 2020 Jun 3.
Abstract
摘要
相似文献
1
Coronavirus Disease-2019 Pandemic: Hopes Ride High on Targeting Known Drugs against Unkown.2019年冠状病毒病大流行：寄厚望于用已知药物对抗未知病毒
Indian J Pharmacol. 2020 Mar-Apr;52(2):75-78. doi: 10.4103/ijp.IJP_309_20. Epub 2020 Jun 3.
2
Why Your Patients' Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVID-19 Is 100% Dangerous.为何您的患者认为羟氯喹和氯喹对新冠病毒病有90%的疗效是极其危险的。
J Clin Pharmacol. 2020 Aug;60(8):949-953. doi: 10.1002/jcph.1687. Epub 2020 Jul 1.
3
A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).呼吁开展随机对照试验以测试氯喹和羟氯喹作为治疗新型冠状病毒病（COVID-19）药物的疗效
Am J Trop Med Hyg. 2020 May;102(5):932-933. doi: 10.4269/ajtmh.20-0230.
4
Chloroquine as a prophylactic agent against COVID-19?氯喹作为 COVID-19 的预防药物？
Int J Antimicrob Agents. 2020 Jun;55(6):105980. doi: 10.1016/j.ijantimicag.2020.105980. Epub 2020 Apr 12.
5
Living evidence in response to controversies about the use of antimalarials in COVID-19.关于在新冠肺炎中使用抗疟药的争议的现存证据。
Rev Esp Cardiol (Engl Ed). 2020 Aug;73(8):693-694. doi: 10.1016/j.rec.2020.05.016. Epub 2020 May 29.
6
COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits.新型冠状病毒肺炎与抗疟药物：弊大于利
Am J Crit Care. 2020 Nov 1;29(6):489-492. doi: 10.4037/ajcc2020694.
7
Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.氯喹和羟氯喹在2019冠状病毒病中的应用及其心血管影响：理解安全性差异以改进临床试验的解读与设计
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008688. doi: 10.1161/CIRCEP.120.008688. Epub 2020 May 21.
8
Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?在疟疾感染率较高的国家，2019冠状病毒病（COVID-19）的发病率是否较低？
Med Hypotheses. 2020 Jul;140:109756. doi: 10.1016/j.mehy.2020.109756. Epub 2020 Apr 22.
9
Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.用于治疗新冠肺炎的氯喹/羟氯喹引发室性心律失常的风险：是否应该使用该药？
Indian Heart J. 2020 Mar-Apr;72(2):131-132. doi: 10.1016/j.ihj.2020.04.006. Epub 2020 Apr 27.
10
Regulators split on antimalarials for COVID-19.监管机构在用于治疗新冠肺炎的抗疟疾药物问题上存在分歧。
Lancet. 2020 Apr 11;395(10231):1179. doi: 10.1016/S0140-6736(20)30817-5.
引用本文的文献
1
Pattern of clinical research in the era of COVID-19 pandemic: A new learning experience for the present as well as future.新冠疫情时代的临床研究模式：当下及未来的全新学习体验。
Indian J Pharmacol. 2020 Jul-Aug;52(4):249-253. doi: 10.4103/ijp.IJP_669_20.
本文引用的文献
1
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.恢复期血浆疗法治疗重症 COVID-19 患者的疗效。
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.
2
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
3
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?高血压和糖尿病患者感染新型冠状病毒肺炎（COVID-19）的风险会增加吗？
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
4
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
5
Liver injury in COVID-19: management and challenges.新型冠状病毒肺炎中的肝损伤：管理与挑战
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430. doi: 10.1016/S2468-1253(20)30057-1. Epub 2020 Mar 4.
6
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
7
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.突破：磷酸氯喹在临床研究中显示出对 COVID-19 相关肺炎的明显疗效。
Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
8
Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.从 2019 年新冠病毒感染患者中提取的临床和生化指标与病毒载量和肺部损伤有关。
Sci China Life Sci. 2020 Mar;63(3):364-374. doi: 10.1007/s11427-020-1643-8. Epub 2020 Feb 9.
9
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.羟氯喹和氯喹的作用机制：对风湿病学的影响。
Nat Rev Rheumatol. 2020 Mar;16(3):155-166. doi: 10.1038/s41584-020-0372-x. Epub 2020 Feb 7.
10
[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].[29例2019新型冠状病毒肺炎患者临床特征分析]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 6;43(0):E005. doi: 10.3760/cma.j.issn.1001-0939.2020.0005.
Zotero 插件